{"id":"W3034621686","doi":"10.1136/annrheumdis-2020-eular.2059","title":"SAT0151 EFFICACY AND SAFETY OF UPADACITINIB VERSUS ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-CHOICE): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Abatacept; Rheumatoid arthritis; Internal medicine; Clinical endpoint; Adalimumab; Adverse effect; Methotrexate; Tofacitinib; Clinical trial; Gastroenterology; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001803448,0.002011474,0.003605954,0.0005011105,0.0004858676,0.001464385,0.000999514,0.001908101,0.007572548],"category_scores_gemma":[0.001642999,0.0008803445,0.002598583,0.0004980388,0.001728507,0.001551846,0.0003867635,0.003201672,0.00145628],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008101499,"about_ca_system_score_gemma":0.001090409,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009661157,"about_ca_topic_score_gemma":0.002009894,"domain_scores_codex":[0.9994017,0.0002959929,0.00004253634,0.0001080475,0.00004582878,0.0001058756],"domain_scores_gemma":[0.9990559,0.0003227853,0.0002029599,0.00007123042,0.00005642787,0.0002906357],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9896924,0.002029178,0.0002787308,0.0003223552,0.0005730964,0.00001731979,0.00002283563,0.0001896509,0.0009576955,0.00005812582,0.0002849013,0.005573742],"study_design_scores_gemma":[0.9665855,0.03150257,0.0007370338,0.00001764569,0.0003612616,0.00001841935,0.00001552594,0.0003193559,0.0002039775,0.0000722257,0.0001539637,0.00001256943],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901326,0.004493418,0.0004955291,0.0004336375,0.0005421192,0.001345085,0.0007991667,0.0001251991,0.001633235],"genre_scores_gemma":[0.9910116,0.002165362,0.0008422882,0.0007691351,0.0004355164,0.001496934,0.001009123,0.0000259497,0.002244013],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007572548,"threshold_uncertainty_score":0.02533275,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05963422971722983,"score_gpt":0.3616093117384592,"score_spread":0.3019750820212294,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}